Business
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and recovery Paridiprubart exhibited consistent safety and tolerability profile TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics (HDTs) for immuno-inflammatory diseases, today announce
About this update from Edesa Biotech, Inc.
[{"type":"image","alt":"Edesa Biotech, Inc.","displaySize":"","headline":null,"caption":"Edesa Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/437f565f3f5588d6751519b1f57c6845"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/t.5EqO96_gAvHppjoVLQxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/437f565f3f5588d6751519b1f57c6845","width":300,"height":157}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Study met primary and secondary endpoints","length":41,"tagName":"p"}]},{"val":[{"type":"text","content":"Paridiprubart demonstrated a relative reduction in the risk of death of 25%","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Treatment provided patients with clinically meaningful improvement in survival and recovery ","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"Paridiprubart exhibited consistent safety and tolerability profile","length":66,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":273,"olType":false},{"type":"text","content":"TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics (HDTs) for immuno-inflammatory diseases, today announced positive results from a Phase 3 study evaluating the company’s drug candidate paridiprubart (EB05) as a treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure.","length":436,"tagName":"p"},{"type":"text","content":"The data from the Phase 3 study demonstrated that paridiprubart met primary and secondary endpoints with statistical significance. Paridiprubart led to a clinically significant reduction in mortality through 60 days, as well as a significant reduction in the proportion of patients requiring invasive mechanical ventilation (IMV).","length":330,"tagName":"p"},{"type":"text","content":"Edesa reported that paridiprubart in the most conservative intention-to-treat (ITT) population met the primary endpoint, demonstrating a statistically significant and clinically meaningful benefit for reduced mortality at 28 days. Patients treated with paridiprubart plus standard of care treatments (SOC) had a lower risk of death (39%) c...